ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Tuesday reported a loss of $62.9 million in its fourth quarter.

The Rockville, Maryland-based company said it had a loss of $1.43 per share.

The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.27 per share.

The biotechnology company posted revenue of $22.2 million in the period, also falling short of Street forecasts. Four analysts surveyed by Zacks expected $27.5 million.

For the year, the company reported a loss of $263.5 million, or $6.02 per share. Revenue was reported as $90.2 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGNX at https://www.zacks.com/ap/RGNX

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News